VanEck非必需消費品TruSector主動型ETF TRUD 深 滬
等待開盤 11-04 09:30:00 美东时间
26.0963
-0.010
-0.04%
華盛通- 最 高26.16
- 今 開26.0199
- 成交量 3.23万股
- 最 低 25.96
- 昨 收 26.1061
- 總市值 9003.22万
- 52周最高 27.4027
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 22.7622
- 委 比 20.00%
- 總股本 345.00万
- 歷史最高 27.4027
- 量 比 0.94
- 振 幅 0.77%
- 歷史最低 22.7622
- 每 手 1
- 風險率 0.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多安进(AMGN.US)Q3电话会：上调全年营收与EPS指引 管理层预计IMDELLTRA一线放量将非常迅速
本次电话会最受关注的问题不是超预期的幅度，而是IMDELLTRA(塔拉塔单抗)在ESMO大会上公布的一线维持治疗数据。
今天 09:26
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S will present new data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting in Phoenix, Arizona. The data highlights EVX-01's broad systemic immunomodulatory effects, including neoantigen-specific T-cell responses, when combined with pembrolizumab. The presentation will occur in both oral and poster sessions on November 6 and 7, 2026. The phase 2 trial demonstrated an Objective Response Rate (O...
11-03 14:00
默沙东第三季度销售额增长5%，受新产品增长推动；2026年每股收益展望更新
默克2026年第三季度销售额增长5%至181亿美元，得益于KEYTRUDA和较新产品的增长；与此同时，费用开支给每股收益（EPS）带来压力，而采购时机则提振了营收。
10-30 00:09
Immutep Quarterly Activities Report Q1 FY27
Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...
10-29 12:00
默克2026年第三季度财报：销售额增长5% 每股收益下降
默克2026年第三季度营收增长5%至180.9亿美元，主要受KEYTRUDA、WINREVAIR、GARDASIL和动物保健业务推动；同时，GAAP每股收益下降12%至2.04美元，非GAAP每股收益下降3%至2.49美元。由于研发费用、产品上市支出、无形资产摊销、重组成本及净利息支出的增加超出了销售额增长，GAAP毛利率收窄至72.9%。默克收窄了全年销售额预期至668亿美元至673亿美元，并将非GAAP每股收益指引区间上调至2.77美元至2.82美元（包含重大一次性业务拓展费用）。
10-29 10:45
Merck Q3 2026 Earnings: Sales Rise 5% as EPS Declines
Merck’s Q3 2026 revenue rose 5% to $18.09 billion, led by KEYTRUDA, WINREVAIR, GARDASIL and Animal Health, while GAAP EPS fell 12% to $2.04 and non-GAAP EPS declined 3% to $2.49. GAAP gross margin narrowed to 72.9% as higher R&D, launch spending, intangible amortization, restructuring and net interest expense outweighed sales growth. Merck narrowed its full-year sales outlook to $66.8 billion-$67.3 billion and raised its non-GAAP EPS range to $2.
10-29 10:43
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology will present late-breaking data on micvotabart pelidotin (MICVO) monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026. An oral presentation by Faye M. Johnson, M.D., Ph.D., will discuss Phase 1 study results, while two posters will highlight preclinical research on MICVO's mechanism of action and combination therapy in HNSCC models...
10-27 12:45
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion A/S announced new three-year clinical data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, showing sustained responses with no tumor progression. The data, building on earlier two-year results with a 75% objective response rate (25% complete response), will be presented at the ESMO 2026 Congress in Madrid and during a webinar on October 29, 2026. The vaccine induced durable immune responses, with 86% of neoantige...
10-19 07:00
Merck secures Japanese approval for subcutaneous Keytruda
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for Keytr...
09-21 20:17
美股夜盘 | VanEck非必需消费品TruSector主动型ETF跌11.69%，最新股价22.72美元
VanEck非必需消费品TruSector主动型ETF跌11.69%，报22.72美元
09-08 09:42
